Characterization of SLE Patient Population from the FORWARD Lupus Registry in the US



OBJECTIVES

The FORWARD Lupus Registry (FLR) is an online longitudinal patient-reported registry in the US, collected through FORWARD, The National Databank for Rheumatic Diseases.¹ Encompassing a broad spectrum of data such as socio-demographics, disease characteristics, Patient-Reported Outcomes (PROs), comorbidities, treatments, and lifestyle patterns, the FLR is a valuable source of patient experience insights. This study describes demographic and clinical characteristics of FLR participants.



RESULTS

- Over the study period, patients completed an average of 9 (SD 9.3) biannual surveys (median 5 [IQR 2-13], maximum 47).
- The FLR cohort included 1,902 patients, 93.6% females. The baseline mean age was 50.1 (SD 13.6) years, with a racial/ethnicity distribution as follows: 73.2% White, 15.4% Black, and 11.4% other.

Table 1. Demographics at Baseline

Variable, mean (SD) or %	Overall (n = 1,902)	Females (n = 1,781)		
Age in years (SD)	50.1 (13.6)	49.7 (13.5)		
Race breakdown (%)				
White	1,200 (73.2%)	1,118 (72.6%)		
Black	252 (15.4%)	243 (15.8%)		
Other ¹	187 (11.4%)	178 (11.6%)		
Marital status (%)				
Married/remarried	1,108 (61.9%)	1,025 (61.1%)		
Other ²	682 (38.1%)	653 (38.9%)		
Total annual income in USD (SD)	51,900 (33,500)	51,600 (33,600)		
Employment status				
Employed	706 (40.9%)	665 (41.1%)		
Other ³	1021 (59.1%)	952 (58.9%)		
Years of education (SD)	14.0 (2.4)	14.0 (2.4)		
Insurance type (%)				
Private	601 (31.6%)	572 (32.1%)		
Medicare	734 (38.6%)	671 (37.7%)		
Medicaid	186 (9.8%)	174 (9.8%)		
Others ⁴	381 (20%)	364 (20.4%)		

¹Hispanic, Asian or Pacific Islander, American Indian or Alaskan Native ²Never married, divorced, separated, widowed ³Unemployed, retired, housework, student, disabled ⁴Preferred Provider Organization (PPO), Health Maintenance Organizations (HMO), no insurance




REFERENCES

1. Frederick Wolfe, Kaleb Michaud, The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank, Rheumatology, Volume 50, Issue 1, January 2011, Pages 16–24, https://doi.org/10.1093/rheumatology/keq155



Mean duration of disease at baseline was 14.4 (SD 11) years

Figure 1. Prevalence of Top Five Comorbidities across the Study Period (1999-2023)*



*Participants could have reported multiple comorbidities over the study period. It was required to only report once to be counted in a comorbidity group.

Figure 2. Proportion of Patients by Treatment across the Study **Period***

Hydroxychloroquine		
Glucocorticoids		
Nonsteroidal anti-inflammatory drugs		
Disease-modifying antirheumatic drug		
Immunosuppressants		
Belimumab	4.2	2%
0.0)%	20.0%

*Participants could have received multiple treatments over the study period. It was required to only report the use of a treatment once to be counted in a treatment group.



CONCLUSION

over an extended period.






Minjee Park ¹ Minjee.park@alirahealth.com		
Sofia Pedro ²		Kal
Jennifer Lann	on ¹	Pat
¹ Alira Health	³ University of Nel	

METHODOLOGY

FLR has an open enrollment, with data collected at enrollment and then every six months from patients via biannual surveys. A retrospective analysis was conducted on data from participants with physician-confirmed SLE who completed at least one biannual survey from 1999 through 2023. Participants with missing data for age or sex were excluded (n=131). Descriptive statistics for baseline observations and prevalence rates for comorbidities and hospitalizations across the study period were analyzed. Subgroup analyses on PROs were conducted based on the first response for every patient that have responded to SLAQ and BILD individually.






Table 2. All-cause ER Visits and Hospitalizations across the **Study Period**

Variable, mean (SD) or %

Patients with at least one E Patients with at least one h Number of hospitalization Average length of stay in

Figure 3. Systemic Lupus Activity Questionnaire (SLAQ) Score¹ (n = 861)





Figure 4. Brief Index of Lupus Damage (BILD) Score² (n = 545)



With data collected over 25 years, the FLR is a rich source of information that allows generation of insights on the health and experiences of people with SLE

- leb Michaud^{2,3}
- tricia Katz^{2,4}

Medical Center, Omaha, NE, USA ⁴University of California San Francisco, San Francisco, CA, USA

	Overall (n = 1,902)
ER visit (%)	1,120 (59%)
hospitalization (%)	921 (48%)
ons (SD)	3.59 (4.27)
n days (SD)	4.48 (2.72)

¹SLAQ score is a composite score that ranges from 0 to 47, with higher scores indicating higher SLE disease activity. SLAQ was administered in FLR since January 2007